Literature DB >> 3780694

Convulsive effects and pharmacokinetics of laudanosine in the rat.

G L Scheepstra, T B Vree, J F Crul, F van de Pol, J Reekers-Ketting.   

Abstract

Laudanosine, which is a degradation product of atracurium, is a convulsant drug in the rat. Laudanosine plasma concentrations were measured by high performance liquid chromatography after administration of both laudanosine and atracurium; protein binding and renal excretion of laudanosine were also determined. A continuous laudanosine infusion of 25 mg kg-1h-1, or less, did not cause convulsions. Eight times ED90 for twitch depression of atracurium gave rise to a laudanosine plasma concentration of less than 8 micrograms ml-1. The convulsive plasma-concentration level for laudanosine was over 17 micrograms ml-1 in the rat. The protein binding of laudanosine was 80%. The kidney excreted 15-20% laudanosine. We conclude that convulsive levels of laudanosine will be very unlikely in any species provided that normal atracurium doses are used no matter how long the procedure.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3780694

Source DB:  PubMed          Journal:  Eur J Anaesthesiol        ISSN: 0265-0215            Impact factor:   4.330


  3 in total

1.  Clinical manifestations and neurodevelopmental outcome following an event of accidental intramuscular injection of atracurium in newborns.

Authors:  Wu-Shiun Hsieh; Hsiu-Min Huang; Steven Peng; Jao-Shwann Liang; Cheung Leung; Geng-Chang Yeh; Chao-Ching Huang; Suh-Fang Jeng
Journal:  Eur J Pediatr       Date:  2006-01-21       Impact factor: 3.183

Review 2.  Adverse effects of neuromuscular blockers and their antagonists.

Authors:  M Naguib; M M Magboul
Journal:  Drug Saf       Date:  1998-02       Impact factor: 5.606

3.  Inadvertent intrathecal injection of atracurium.

Authors:  Nahid Zirak; Ghasem Soltani; Naiere Ghomian; Mohamad Reza Hasanpour; Zahra Mashayekhi
Journal:  Saudi J Anaesth       Date:  2011-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.